0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Rift Valley fever virus (RVFV), a recognized category A priority pathogen, causes large outbreaks of Rift Valley fever with some fatalities in humans in humans and huge economic losses in livestock. As wild-type RVFV must be handled in BSL-3 or BSL-4 laboratories, we constructed a high-titer vesicular stomatitis virus (VSV) pseudotype bearing RVFV envelope glycoproteins to detect neutralizing antibodies in vitro under BSL-2 conditions. The neutralizing properties of 39 amino acid mutant sites that have occurred naturally over time in the RVFV envelope glycoproteins were analyzed with their corresponding pseudoviral mutants separately. Compared with the results in the primary strain, the variants showed no statistically significant differences. We next established a Balb/c mouse pseudovirus infection model for detecting neutralizing antibodies against pseudovirus. Five immunizations with pseudoviral DNA protected the mice from infection with the pseudovirus. Bioluminescence imaging, which we used to evaluate viral dissemination and distribution in the mice, showed a good relationship between the neutralizing antibodies titers in vitro. These pseudovirus methods will allow for the safe determination of neutralizing antibodies in vivo and in vitro, and will assist with studies on vaccines and drugs against RVFV with the long term objective of Rift Valley fever prevention.

          Related collections

          Author and article information

          Journal
          Hum Vaccin Immunother
          Hum Vaccin Immunother
          KHVI
          khvi20
          Human Vaccines & Immunotherapeutics
          Taylor & Francis
          2164-5515
          2164-554X
          2019
          20 June 2019
          : 15
          : 10
          : 2286-2294
          Affiliations
          [a ] Division of HIV/AIDS and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC) , Beijing, China
          [b ] National Engineering Technology Research Center of Combination Vaccines , Wuhan, China
          [c ] China National Biotec Group Company Limited , Beijing, China
          Author notes
          CONTACT Youchun Wang wangyc@ 123456nifdc.org.cn National Institutes for Food and Drug Control , No. 31 Huatuo Road, Beijing 102629, China
          Xiaoming Yang yangxiaoming@ 123456sinopharm.com Wuhan Institute of Biological Products Co.,LTD , No.1 Zhengdian Gold Industrial Park Road, Jiangxia District, Wuhan 430070, China
          [*]

          These authors contributed equally to the work.

          Article
          PMC6816429 PMC6816429 6816429 1627820
          10.1080/21645515.2019.1627820
          6816429
          31170027
          © 2019 Taylor & Francis Group, LLC
          Page count
          Figures: 4, Tables: 1, References: 41, Pages: 9
          Funding
          Funded by: National Science and Technology Major Projects of Infectious Disease funds of China
          Award ID: 2017ZX10304402
          This work was supported by the National Science and Technology Major Projects of Infectious Disease funds of China (grants 2017ZX10304402).
          Categories
          Research Paper

          Comments

          Comment on this article